Fine Control of In Vivo Magnetic Hyperthermia Using Iron Oxide Nanoparticles with Different Coatings and Degree of Aggregation

The clinical implementation of magnetic hyperthermia has experienced little progress since the first clinical trial was completed in 2005. Some of the hurdles to overcome are the reliable production of magnetic nanoparticles with controlled properties and the control of the temperature at the target...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 14; no. 8; p. 1526
Main Authors Luengo, Yurena, Díaz-Riascos, Zamira V, García-Soriano, David, Teran, Francisco J, Artés-Ibáñez, Emilio J, Ibarrola, Oihane, Somoza, Álvaro, Miranda, Rodolfo, Schwartz, Simó, Abasolo, Ibane, Salas, Gorka
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 22.07.2022
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The clinical implementation of magnetic hyperthermia has experienced little progress since the first clinical trial was completed in 2005. Some of the hurdles to overcome are the reliable production of magnetic nanoparticles with controlled properties and the control of the temperature at the target tissue in vivo. Here, forty samples of iron oxide superparamagnetic nanoparticles were prepared by similar methods and thoroughly characterized in terms of size, aggregation degree, and heating response. Selected samples were intratumorally administered in animals with subcutaneous xenografts of human pancreatic cancer. In vivo experiments showed that it is possible to control the rise in temperature by modulating the field intensity during in vivo magnetic hyperthermia protocols. The procedure does not require sophisticated materials and it can be easily implemented by researchers or practitioners working in magnetic hyperthermia therapies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14081526